Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD
Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin‐exacerbated respiratory disease (AERD). Objective To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Methods Thirty‐two asthmat...
Saved in:
Published in | Clinical and experimental allergy Vol. 43; no. 7; pp. 730 - 740 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.07.2013
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0954-7894 1365-2222 1365-2222 |
DOI | 10.1111/cea.12096 |
Cover
Abstract | Summary
Background
Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin‐exacerbated respiratory disease (AERD).
Objective
To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics.
Methods
Thirty‐two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine‐aspirin nasal provocation test (L‐ASA NPT) and 14 aspirin‐tolerant asthma (ATA) patients who showed negative responses to the L‐ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L‐ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L‐ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups.
Results
Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up‐regulation of apolipoprotein A1 (ApoA1), α2‐macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients.
Conclusion
Eosinophil activation occurred in early and late responses after L‐ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation. |
---|---|
AbstractList | Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). Objective To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Methods Thirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Results Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), [alpha]2-macroglobulin ([alpha]2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, [alpha]2M and CP levels during the early response in AERD patients. Conclusion Eosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, [alpha]2M and CP as well as CysLT may be involved in eosinophilic inflammation. [PUBLICATION ABSTRACT] Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Thirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), alpha 2-macroglobulin ( alpha 2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, alpha 2M and CP levels during the early response in AERD patients. Eosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, alpha 2M and CP as well as CysLT may be involved in eosinophilic inflammation. Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD).BACKGROUNDEosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD).To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics.OBJECTIVETo investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics.Thirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups.METHODSThirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups.Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), α2-macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients.RESULTSEosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), α2-macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients.Eosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation.CONCLUSIONEosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation. Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Thirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), α2-macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients. Eosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation. Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin‐exacerbated respiratory disease (AERD). Objective To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Methods Thirty‐two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine‐aspirin nasal provocation test (L‐ASA NPT) and 14 aspirin‐tolerant asthma (ATA) patients who showed negative responses to the L‐ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L‐ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L‐ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Results Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up‐regulation of apolipoprotein A1 (ApoA1), α2‐macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients. Conclusion Eosinophil activation occurred in early and late responses after L‐ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation. |
Author | Park, H.-S. Shin, Y.-S. Ye, Y.-M. Choi, G.-S. Kim, J.-H. Kim, S.-H. |
Author_xml | – sequence: 1 givenname: G.-S. surname: Choi fullname: Choi, G.-S. organization: Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea – sequence: 2 givenname: J.-H. surname: Kim fullname: Kim, J.-H. organization: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea – sequence: 3 givenname: Y.-S. surname: Shin fullname: Shin, Y.-S. organization: Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea – sequence: 4 givenname: Y.-M. surname: Ye fullname: Ye, Y.-M. organization: Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea – sequence: 5 givenname: S.-H. surname: Kim fullname: Kim, S.-H. organization: Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea – sequence: 6 givenname: H.-S. surname: Park fullname: Park, H.-S. email: Hae-Sim Park, Department of Allergy and Clinical Immunology, Ajou University School of Medicine164 Worldcup-ro, Yeongtong-gu, Suwon 443-721, Korea., hspark@ajou.ac.kr organization: Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23786280$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1uEzEYRS1URNPCghdAI7GBxbT-Gf8toyQURFQkBHRpOZ5vVJeJPdgzhb49bpOwqEDi23hzzpV87wk6CjEAQi8JPiPlzh3YM0KxFk_QjDDBa1ruCM2w5k0tlW6O0UnONxhjxrV6ho4pk0pQhWfoahWzD3G49n1l3ehv7ehjqGxoqxBvoa-20Ho7xpQrH6rxGiqbB598qH1oJwcFs9n2VYI8xJDhnpqvPi-fo6ed7TO82L-n6Ou71ZfF-3r96eLDYr6uXaOxqKXTG6Wwa5hTim0UthIYda1TmNBNhxulOitJ41jLqZJcCAe6xY1lSjmAjp2iN7vcIcUfE-TRbH120Pc2QJyyIUxrTXEp5T9QiQUTosEFff0IvYlTCuUjhnCqOcWU60K92lPTptRkhuS3Nt2ZQ7sFON8BLsWcE3TG-fGh4DFZ3xuCzf1-puxnHvYrxttHxiH0b-w-_afv4e7foFms5gej3hk-j_Drj2HTdyMkk9xcXV6Yb4ItL8XHpVmz3-7ctkA |
CitedBy_id | crossref_primary_10_1080_02770903_2019_1652644 crossref_primary_10_1007_s11882_015_0569_2 crossref_primary_10_1021_pr500935s crossref_primary_10_1111_all_13075 crossref_primary_10_1016_j_alit_2024_08_008 crossref_primary_10_1111_all_14620 crossref_primary_10_56782_pps_38 crossref_primary_10_2500_ajra_2015_29_4154 crossref_primary_10_1007_s00405_016_4273_1 crossref_primary_10_1016_j_bjorl_2015_01_003 crossref_primary_10_1186_s12970_015_0085_8 crossref_primary_10_3390_ijms23105703 crossref_primary_10_1016_j_lfs_2020_118973 crossref_primary_10_1016_j_rmed_2018_01_002 crossref_primary_10_1111_cea_12442 crossref_primary_10_1097_ACI_0000000000000122 crossref_primary_10_4168_aair_2016_8_6_481 crossref_primary_10_1097_ACI_0000000000000021 crossref_primary_10_1097_MCP_0000000000000010 crossref_primary_10_3389_fgene_2018_00363 crossref_primary_10_1002_prca_201300108 crossref_primary_10_1136_jramc_2015_000608 crossref_primary_10_1097_MCP_0000000000000328 crossref_primary_10_1016_j_anai_2015_02_009 crossref_primary_10_1186_s12931_018_0909_6 crossref_primary_10_1016_j_clim_2015_05_012 crossref_primary_10_1586_1744666X_2015_1039940 crossref_primary_10_3390_ijms22094377 crossref_primary_10_1016_j_jim_2021_113101 crossref_primary_10_1080_17476348_2018_1417843 crossref_primary_10_4168_aair_2022_14_5_479 crossref_primary_10_1080_02770903_2017_1341522 |
Cites_doi | 10.1371/journal.pone.0022711 10.1042/bj2450781 10.1164/ajrccm.156.5.9702072 10.1385/CRIAI:24:2:113 10.1016/S0021-9258(18)80094-1 10.1136/thorax.55.11.921 10.1002/pmic.200300562 10.1161/ATVBAHA.112.300135 10.1159/000312669 10.1164/rccm.201010-1623OC 10.1111/j.1398-9995.2006.00993.x 10.1111/j.1365-2222.2008.03190.x 10.1155/2000/907478 10.3349/ymj.2009.50.6.744 10.1183/09031936.00138707 10.1016/B978-0-323-05659-5.00069-3 10.1164/rccm.200505-740OC 10.1080/01902140802220625 10.1016/j.jaci.2006.07.024 10.1111/j.1398-9995.2007.01409.x 10.1111/j.1365-2222.2009.03216.x 10.1111/j.1398-9995.2009.02158.x 10.1111/j.1365-2222.1995.tb01000.x 10.1159/000070474 10.4193/Rhino50E2 10.4168/aair.2012.4.2.68 10.1034/j.1398-9995.2003.00276.x 10.4168/aair.2011.3.1.3 10.1016/S0021-9258(18)80072-2 10.1164/ajrccm.149.4.8143059 10.1016/S0021-9258(19)57337-9 10.1016/S0952-3278(03)00074-7 10.1016/j.jaci.2009.12.977 10.1016/S1081-1206(10)60615-1 10.1007/s11882-006-0035-2 10.1067/mai.2003.1487 10.1111/j.1398-9995.2011.02557.x 10.1378/chest.128.5.3127 10.1016/j.atherosclerosis.2005.11.035 10.1067/mai.2003.25 10.1002/jlb.55.2.183 10.1046/j.1365-2222.2002.01384.x 10.1016/j.jaci.2005.08.035 10.1034/j.1398-9995.2002.t01-1-13447.x 10.1016/S1081-1206(10)62815-3 10.1194/jlr.M004549 10.1016/S1081-1206(10)62084-4 10.1016/j.jaci.2008.07.034 10.1111/j.1365-2222.1996.tb00612.x 10.1136/thx.2008.101196 10.1378/chest.11-0158 |
ContentType | Journal Article |
Copyright | 2013 John Wiley & Sons Ltd 2013 John Wiley & Sons Ltd. Copyright © 2013 John Wiley & Sons Ltd |
Copyright_xml | – notice: 2013 John Wiley & Sons Ltd – notice: 2013 John Wiley & Sons Ltd. – notice: Copyright © 2013 John Wiley & Sons Ltd |
DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
DOI | 10.1111/cea.12096 |
DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1365-2222 |
EndPage | 740 |
ExternalDocumentID | 3317426841 23786280 10_1111_cea_12096 CEA12096 ark_67375_WNG_V63DN6KD_L |
Genre | article Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: KOSEF – fundername: Korea government funderid: 2009‐0078646 |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 29B 31~ 33P 36B 3O- 3SF 4.4 4P2 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AHMBA AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOETA ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBB EBC EBD EBS EBX EDH EJD EMB EMK EMOBN ESTFP ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH YUY ZGI ZXP ZZTAW ~IA ~WT AAHHS ACCFJ ADZOD AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE WRC WUP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
ID | FETCH-LOGICAL-c4906-7c9b880c43c883b80a7e32cdc8012bf0488fa714c3d5287566ce9d04a388ceef3 |
IEDL.DBID | DR2 |
ISSN | 0954-7894 1365-2222 |
IngestDate | Sun Sep 28 06:16:31 EDT 2025 Fri Sep 05 08:46:28 EDT 2025 Sun Jul 13 04:00:23 EDT 2025 Mon Jul 21 06:05:09 EDT 2025 Tue Jul 01 02:53:22 EDT 2025 Thu Apr 24 23:01:28 EDT 2025 Wed Jan 22 16:36:49 EST 2025 Tue Sep 09 05:32:15 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2013 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4906-7c9b880c43c883b80a7e32cdc8012bf0488fa714c3d5287566ce9d04a388ceef3 |
Notes | ark:/67375/WNG-V63DN6KD-L ArticleID:CEA12096 istex:7E95D2EDF5B8F0ED3334DAB3590A3CD26F4B9EB9 KOSEF Korea government - No. 2009-0078646 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
PMID | 23786280 |
PQID | 1529520259 |
PQPubID | 36521 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1399920365 proquest_miscellaneous_1370636640 proquest_journals_1529520259 pubmed_primary_23786280 crossref_citationtrail_10_1111_cea_12096 crossref_primary_10_1111_cea_12096 wiley_primary_10_1111_cea_12096_CEA12096 istex_primary_ark_67375_WNG_V63DN6KD_L |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | July 2013 |
PublicationDateYYYYMMDD | 2013-07-01 |
PublicationDate_xml | – month: 07 year: 2013 text: July 2013 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | Clinical and experimental allergy |
PublicationTitleAlternate | Clin Exp Allergy |
PublicationYear | 2013 |
Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
References | Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997; 156:1384-9. Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010; 85:336-49. Gaber F, Daham K, Higashi A et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63:1076-82. Yamashita T, Tsuji H, Maeda N, Tomoda K, Kumazawa T. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinol Suppl 1989; 8:15-24. Sladek K, Dworski R, Soja J et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149:940-6. Palikhe NS, Kim JH, Park HS. Update on recent advances in the management of aspirin exacerbated respiratory disease. Yonsei Med J 2009; 50:744-50. Min JW, Jang AS, Park SM et al. Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients. Chest 2005; 128:3127-32. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62:1111-8. Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996; 26:807-14. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006; 187:238-50. Wang W, Xu H, Shi Y et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res 2010; 51:2560-70. Cho YM, Bae SH, Choi BK et al. Differential expression of the liver proteome in senescence accelerated mice. Proteomics 2003; 3:1883-94. Fuentes-Beltran A, Montes-Vizuet R, Valencia-Maqueda E, Negrete-García MC, García-Cruz Mde L, Teran LM. Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients. Clin Exp Allergy 2009; 39:491-9. Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084-91. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89:474-8. Fregonese L, Silvestri M, Sabatini F, Rossi GA. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 2002; 32:745-50. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-78. Huang SS, O'Grady P, Huang JS. Human transforming growth factor beta-alpha 2-macroglobulin complex is a latent form of transforming growth factor beta. J Biol Chem 1988; 263:1535-41. Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24:113-24. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003; 111:S18-34. Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res 2012; 4:68-79. Picado C. Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006; 6:198-202. Reddy VY, Pizzo SV, Weiss SJ. Functional inactivation and structural disruption of human alpha 2-macroglobulin by neutrophils and eosinophils. J Biol Chem 1989; 264:13801-9. Lee SH, Rhim T, Choi YS et al. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med 2006; 173:370-8. Mascia K, Haselkorn T, Deniz YM et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970-5. Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol 1994; 55:183-91. Park HS, Nahm DH, Park K, Suh KS, Yim HE. Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin-sensitive asthmatic patients. Ann Allergy Asthma Immunol 1998; 81:219-24. Ben-Yehuda C, Bader R, Puxeddu I, Levi-Schaffer F, Breuer R, Berkman N. Airway eosinophil accumulation and eotaxin-2/CCL24 expression following allergen challenge in BALB/c mice. Exp Lung Res 2008; 34:467-79. Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids 2003; 69:135-43. Hur GY, Choi GS, Sheen SS et al. Serum ferritin and transferrin levels as serologic markers of methylene diphenyl diisocyanate-induced occupational asthma. J Allergy Clin Immunol 2008; 122:774-80. Vural H, Uzun K. Serum and red blood cell antioxidant status in patients with bronchial asthma. Can Respir J 2000; 7:476-80. Kim TH, Lee JY, Park JS et al. Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease. PLoS ONE 2011; 6:e22711. Fokkens WJ, Lund VJ, Mullol J et al. EPOS2012:European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50:1-12. Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma. Allergy 2002; 57:632-5. Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol 2007; 99:13-21. Hemelaers L, Henket M, Sele J, Bureau F, Louis R. Cysteinyl-leukotrienes contribute to sputum eosinophil chemotactic activity in asthmatics. Allergy 2006; 61:136-9. Nagata M, Saito K. The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways. Int Arch Allergy Immunol 2003; 131:7-10. Pods R, Ross D, van Hulst S, Rudack C, Maune S. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003; 58:1165-70. Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol 2012; 32:2561-5. Yao X, Remaley AT, Levine SJ. New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma. Chest 2011; 140:1048-54. Verrills NM, Irwin JA, He XY et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1633-43. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264:11539-42. Palikhe NS, Kim SH, Cho BY, Ye YM, Choi GS, Park HS. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy 2010; 65:338-46. Park HS. Early and late onset asthmatic responses following lysine-aspirin inhalation in aspirin-sensitive asthmatic patients. Clin Exp Allergy 1995; 25:38-40. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011; 3:3-10. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-21. Choi GS, Park HJ, Hur GY et al. Vascular endothelial growth factor in allergen-induced nasal inflammation. Clin Exp Allergy 2009; 39:655-61. Peterson CG, Venge P. Interaction and complex-formation between the eosinophil cationic protein and alpha 2-macroglobulin. Biochem J 1987; 245:781-7. Kowalski ML, Makowska JS, Blanca M et al. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011; 66:818-29. Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55:921-4. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118:773-86. 2002; 57 1997; 156 2000; 7 2003; 58 2006; 173 2008; 34 1998; 81 1988; 263 2008; 31 2003; 111 2010; 65 1994; 149 2006; 61 2009; 50 1995; 25 2002; 89 2000; 55 1989; 264 2003; 3 2011; 66 2007; 62 2008; 63 1996; 26 1987; 245 2010; 125 2005; 116 2002; 32 1989; 8 2009 2006; 6 2011; 3 2008; 122 2007; 99 2006; 118 2011; 6 2010; 85 2012; 32 2003; 131 2012; 50 2005; 128 2003; 24 2003; 69 1994; 55 2006; 187 2011; 140 2012; 4 2011; 183 2010; 51 2009; 39 e_1_2_7_5_1 e_1_2_7_3_1 Huang SS (e_1_2_7_48_1) 1988; 263 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_17_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_49_1 e_1_2_7_28_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_52_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_37_1 e_1_2_7_39_1 Reddy VY (e_1_2_7_50_1) 1989; 264 e_1_2_7_6_1 e_1_2_7_4_1 e_1_2_7_8_1 e_1_2_7_18_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_10_1 e_1_2_7_46_1 Yamashita T (e_1_2_7_9_1) 1989; 8 e_1_2_7_27_1 e_1_2_7_29_1 e_1_2_7_51_1 e_1_2_7_30_1 e_1_2_7_53_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_38_1 |
References_xml | – reference: Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89:474-8. – reference: Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-78. – reference: Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol 1994; 55:183-91. – reference: Ben-Yehuda C, Bader R, Puxeddu I, Levi-Schaffer F, Breuer R, Berkman N. Airway eosinophil accumulation and eotaxin-2/CCL24 expression following allergen challenge in BALB/c mice. Exp Lung Res 2008; 34:467-79. – reference: Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084-91. – reference: Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264:11539-42. – reference: Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24:113-24. – reference: Reddy VY, Pizzo SV, Weiss SJ. Functional inactivation and structural disruption of human alpha 2-macroglobulin by neutrophils and eosinophils. J Biol Chem 1989; 264:13801-9. – reference: Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids 2003; 69:135-43. – reference: Park HS, Nahm DH, Park K, Suh KS, Yim HE. Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin-sensitive asthmatic patients. Ann Allergy Asthma Immunol 1998; 81:219-24. – reference: Lee SH, Rhim T, Choi YS et al. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med 2006; 173:370-8. – reference: Fuentes-Beltran A, Montes-Vizuet R, Valencia-Maqueda E, Negrete-García MC, García-Cruz Mde L, Teran LM. Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients. Clin Exp Allergy 2009; 39:491-9. – reference: Huang SS, O'Grady P, Huang JS. Human transforming growth factor beta-alpha 2-macroglobulin complex is a latent form of transforming growth factor beta. J Biol Chem 1988; 263:1535-41. – reference: Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62:1111-8. – reference: Peterson CG, Venge P. Interaction and complex-formation between the eosinophil cationic protein and alpha 2-macroglobulin. Biochem J 1987; 245:781-7. – reference: Gaber F, Daham K, Higashi A et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63:1076-82. – reference: Kim TH, Lee JY, Park JS et al. Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease. PLoS ONE 2011; 6:e22711. – reference: Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55:921-4. – reference: Yao X, Remaley AT, Levine SJ. New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma. Chest 2011; 140:1048-54. – reference: Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma. Allergy 2002; 57:632-5. – reference: Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011; 3:3-10. – reference: Sladek K, Dworski R, Soja J et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149:940-6. – reference: Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol 2007; 99:13-21. – reference: Palikhe NS, Kim JH, Park HS. Update on recent advances in the management of aspirin exacerbated respiratory disease. Yonsei Med J 2009; 50:744-50. – reference: Fregonese L, Silvestri M, Sabatini F, Rossi GA. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 2002; 32:745-50. – reference: Picado C. Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006; 6:198-202. – reference: Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-21. – reference: Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118:773-86. – reference: Mascia K, Haselkorn T, Deniz YM et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970-5. – reference: Park HS. Early and late onset asthmatic responses following lysine-aspirin inhalation in aspirin-sensitive asthmatic patients. Clin Exp Allergy 1995; 25:38-40. – reference: Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996; 26:807-14. – reference: Vural H, Uzun K. Serum and red blood cell antioxidant status in patients with bronchial asthma. Can Respir J 2000; 7:476-80. – reference: Kowalski ML, Makowska JS, Blanca M et al. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011; 66:818-29. – reference: Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006; 187:238-50. – reference: Cho YM, Bae SH, Choi BK et al. Differential expression of the liver proteome in senescence accelerated mice. Proteomics 2003; 3:1883-94. – reference: Palikhe NS, Kim SH, Cho BY, Ye YM, Choi GS, Park HS. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy 2010; 65:338-46. – reference: Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003; 111:S18-34. – reference: Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997; 156:1384-9. – reference: Choi GS, Park HJ, Hur GY et al. Vascular endothelial growth factor in allergen-induced nasal inflammation. Clin Exp Allergy 2009; 39:655-61. – reference: Pods R, Ross D, van Hulst S, Rudack C, Maune S. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003; 58:1165-70. – reference: Hur GY, Choi GS, Sheen SS et al. Serum ferritin and transferrin levels as serologic markers of methylene diphenyl diisocyanate-induced occupational asthma. J Allergy Clin Immunol 2008; 122:774-80. – reference: Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010; 85:336-49. – reference: Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res 2012; 4:68-79. – reference: Verrills NM, Irwin JA, He XY et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1633-43. – reference: Wang W, Xu H, Shi Y et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res 2010; 51:2560-70. – reference: Nagata M, Saito K. The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways. Int Arch Allergy Immunol 2003; 131:7-10. – reference: Min JW, Jang AS, Park SM et al. Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients. Chest 2005; 128:3127-32. – reference: Fokkens WJ, Lund VJ, Mullol J et al. EPOS2012:European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50:1-12. – reference: Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol 2012; 32:2561-5. – reference: Yamashita T, Tsuji H, Maeda N, Tomoda K, Kumazawa T. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinol Suppl 1989; 8:15-24. – reference: Hemelaers L, Henket M, Sele J, Bureau F, Louis R. Cysteinyl-leukotrienes contribute to sputum eosinophil chemotactic activity in asthmatics. Allergy 2006; 61:136-9. – volume: 111 start-page: S18 year: 2003 end-page: 34 article-title: Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling publication-title: J Allergy Clin Immunol – volume: 245 start-page: 781 year: 1987 end-page: 7 article-title: Interaction and complex‐formation between the eosinophil cationic protein and alpha 2‐macroglobulin publication-title: Biochem J – volume: 55 start-page: 921 year: 2000 end-page: 4 article-title: Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry publication-title: Thorax – volume: 62 start-page: 1111 year: 2007 end-page: 8 article-title: EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity publication-title: Allergy – volume: 131 start-page: 7 year: 2003 end-page: 10 article-title: The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways publication-title: Int Arch Allergy Immunol – volume: 156 start-page: 1384 year: 1997 end-page: 9 article-title: Expression of interleukin‐5 and granulocyte‐macrophage colony‐stimulating factor in aspirin‐sensitive and non‐aspirin‐sensitive asthmatic airways publication-title: Am J Respir Crit Care Med – volume: 125 start-page: 1084 year: 2010 end-page: 91 article-title: Profile of eicosanoid generation in aspirin‐intolerant asthma and anaphylaxis assessed by new biomarkers publication-title: J Allergy Clin Immunol – volume: 111 start-page: 913 year: 2003 end-page: 21 article-title: Aspirin‐induced asthma: advances in pathogenesis, diagnosis, and management publication-title: J Allergy Clin Immunol – volume: 50 start-page: 1 year: 2012 end-page: 12 article-title: EPOS2012:European Position Paper on Rhinosinusitis and Nasal Polyps 2012 publication-title: A summary for otorhinolaryngologists. Rhinology – volume: 26 start-page: 807 year: 1996 end-page: 14 article-title: Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA‐sensitive patients publication-title: Clin Exp Allergy – volume: 25 start-page: 38 year: 1995 end-page: 40 article-title: Early and late onset asthmatic responses following lysine‐aspirin inhalation in aspirin‐sensitive asthmatic patients publication-title: Clin Exp Allergy – volume: 6 start-page: e22711 year: 2011 article-title: Fatty acid binding protein 1 is related with development of aspirin‐exacerbated respiratory disease publication-title: PLoS ONE – volume: 69 start-page: 135 year: 2003 end-page: 43 article-title: Eosinophils and cysteinyl leukotrienes publication-title: Prostaglandins Leukot Essent Fatty Acids – volume: 263 start-page: 1535 year: 1988 end-page: 41 article-title: Human transforming growth factor beta–alpha 2‐macroglobulin complex is a latent form of transforming growth factor beta publication-title: J Biol Chem – volume: 4 start-page: 68 year: 2012 end-page: 79 article-title: Eosinophil development, regulation of eosinophil‐specific genes, and role of eosinophils in the pathogenesis of asthma publication-title: Allergy Asthma Immunol Res – volume: 61 start-page: 136 year: 2006 end-page: 9 article-title: Cysteinyl‐leukotrienes contribute to sputum eosinophil chemotactic activity in asthmatics publication-title: Allergy – volume: 264 start-page: 11539 year: 1989 end-page: 42 article-title: Alpha‐macroglobulins: structure, shape, and mechanism of proteinase complex formation publication-title: J Biol Chem – volume: 183 start-page: 1633 year: 2011 end-page: 43 article-title: Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease publication-title: Am J Respir Crit Care Med – volume: 187 start-page: 238 year: 2006 end-page: 50 article-title: Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? publication-title: Atherosclerosis – volume: 50 start-page: 744 year: 2009 end-page: 50 article-title: Update on recent advances in the management of aspirin exacerbated respiratory disease publication-title: Yonsei Med J – volume: 173 start-page: 370 year: 2006 end-page: 8 article-title: Complement C3a and C4a increased in plasma of patients with aspirin‐induced asthma publication-title: Am J Respir Crit Care Med – volume: 39 start-page: 655 year: 2009 end-page: 61 article-title: Vascular endothelial growth factor in allergen‐induced nasal inflammation publication-title: Clin Exp Allergy – volume: 7 start-page: 476 year: 2000 end-page: 80 article-title: Serum and red blood cell antioxidant status in patients with bronchial asthma publication-title: Can Respir J – volume: 31 start-page: 143 year: 2008 end-page: 78 article-title: Global strategy for asthma management and prevention: GINA executive summary publication-title: Eur Respir J – volume: 99 start-page: 13 year: 2007 end-page: 21 article-title: Pathogenesis, diagnosis, and treatment of aspirin intolerance publication-title: Ann Allergy Asthma Immunol – volume: 89 start-page: 474 year: 2002 end-page: 8 article-title: The natural history and clinical characteristics of aspirin‐exacerbated respiratory disease publication-title: Ann Allergy Asthma Immunol – volume: 85 start-page: 336 year: 2010 end-page: 49 article-title: Cysteinyl leukotrienes and their receptors: molecular and functional characteristics publication-title: Pharmacology – volume: 24 start-page: 113 year: 2003 end-page: 24 article-title: Natural history and clinical features of aspirin‐exacerbated respiratory disease publication-title: Clin Rev Allergy Immunol – volume: 34 start-page: 467 year: 2008 end-page: 79 article-title: Airway eosinophil accumulation and eotaxin‐2/CCL24 expression following allergen challenge in BALB/c mice publication-title: Exp Lung Res – volume: 57 start-page: 632 year: 2002 end-page: 5 article-title: Nasal provocation test with aspirin: a sensitive and safe method to diagnose aspirin‐induced asthma publication-title: Allergy – volume: 81 start-page: 219 year: 1998 end-page: 24 article-title: Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin‐sensitive asthmatic patients publication-title: Ann Allergy Asthma Immunol – volume: 3 start-page: 3 year: 2011 end-page: 10 article-title: Aspirin‐exacerbated respiratory disease: evaluation and management publication-title: Allergy Asthma Immunol Res – volume: 116 start-page: 970 year: 2005 end-page: 5 article-title: Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult‐to‐treat asthma publication-title: J Allergy Clin Immunol – volume: 55 start-page: 183 year: 1994 end-page: 91 article-title: Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility publication-title: J Leukoc Biol – volume: 58 start-page: 1165 year: 2003 end-page: 70 article-title: RANTES, eotaxin and eotaxin‐2 expression and production in patients with aspirin triad publication-title: Allergy – volume: 140 start-page: 1048 year: 2011 end-page: 54 article-title: New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma publication-title: Chest – start-page: 1227 year: 2009 end-page: 40 – volume: 8 start-page: 15 year: 1989 end-page: 24 article-title: Etiology of nasal polyps associated with aspirin‐sensitive asthma publication-title: Rhinol Suppl – volume: 65 start-page: 338 year: 2010 end-page: 46 article-title: Genetic variability in CRTH2 polymorphism increases eotaxin‐2 levels in patients with aspirin exacerbated respiratory disease publication-title: Allergy – volume: 6 start-page: 198 year: 2006 end-page: 202 article-title: Mechanisms of aspirin sensitivity publication-title: Curr Allergy Asthma Rep – volume: 264 start-page: 13801 year: 1989 end-page: 9 article-title: Functional inactivation and structural disruption of human alpha 2‐macroglobulin by neutrophils and eosinophils publication-title: J Biol Chem – volume: 118 start-page: 773 year: 2006 end-page: 86 article-title: Clinical and pathologic perspectives on aspirin sensitivity and asthma publication-title: J Allergy Clin Immunol – volume: 32 start-page: 745 year: 2002 end-page: 50 article-title: Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor‐mediated mechanism publication-title: Clin Exp Allergy – volume: 66 start-page: 818 year: 2011 end-page: 29 article-title: Hypersensitivity to non‐steroidal anti‐inflammatory drugs (NSAIDs) ‐ classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA* publication-title: Allergy – volume: 39 start-page: 491 year: 2009 end-page: 9 article-title: Chemokine CC‐ligand 5 production and eosinophil activation into the upper airways of aspirin‐sensitive patients publication-title: Clin Exp Allergy – volume: 32 start-page: 2561 year: 2012 end-page: 5 article-title: High density lipoprotein biogenesis, cholesterol efflux, and immune cell function publication-title: Arterioscler Thromb Vasc Biol – volume: 3 start-page: 1883 year: 2003 end-page: 94 article-title: Differential expression of the liver proteome in senescence accelerated mice publication-title: Proteomics – volume: 128 start-page: 3127 year: 2005 end-page: 32 article-title: Comparison of plasma eotaxin family level in aspirin‐induced and aspirin‐tolerant asthma patients publication-title: Chest – volume: 149 start-page: 940 year: 1994 end-page: 6 article-title: Eicosanoids in bronchoalveolar lavage fluid of aspirin‐intolerant patients with asthma after aspirin challenge publication-title: Am J Respir Crit Care Med – volume: 122 start-page: 774 year: 2008 end-page: 80 article-title: Serum ferritin and transferrin levels as serologic markers of methylene diphenyl diisocyanate‐induced occupational asthma publication-title: J Allergy Clin Immunol – volume: 51 start-page: 2560 year: 2010 end-page: 70 article-title: Genetic deletion of apolipoprotein A‐I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung publication-title: J Lipid Res – volume: 63 start-page: 1076 year: 2008 end-page: 82 article-title: Increased levels of cysteinyl‐leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin‐intolerant asthma publication-title: Thorax – ident: e_1_2_7_42_1 doi: 10.1371/journal.pone.0022711 – ident: e_1_2_7_49_1 doi: 10.1042/bj2450781 – ident: e_1_2_7_40_1 doi: 10.1164/ajrccm.156.5.9702072 – ident: e_1_2_7_6_1 doi: 10.1385/CRIAI:24:2:113 – ident: e_1_2_7_47_1 doi: 10.1016/S0021-9258(18)80094-1 – ident: e_1_2_7_24_1 doi: 10.1136/thorax.55.11.921 – ident: e_1_2_7_29_1 doi: 10.1002/pmic.200300562 – ident: e_1_2_7_44_1 doi: 10.1161/ATVBAHA.112.300135 – ident: e_1_2_7_13_1 doi: 10.1159/000312669 – ident: e_1_2_7_52_1 doi: 10.1164/rccm.201010-1623OC – ident: e_1_2_7_14_1 doi: 10.1111/j.1398-9995.2006.00993.x – ident: e_1_2_7_41_1 doi: 10.1111/j.1365-2222.2008.03190.x – ident: e_1_2_7_53_1 doi: 10.1155/2000/907478 – ident: e_1_2_7_33_1 doi: 10.3349/ymj.2009.50.6.744 – ident: e_1_2_7_21_1 doi: 10.1183/09031936.00138707 – volume: 8 start-page: 15 year: 1989 ident: e_1_2_7_9_1 article-title: Etiology of nasal polyps associated with aspirin‐sensitive asthma publication-title: Rhinol Suppl – ident: e_1_2_7_2_1 doi: 10.1016/B978-0-323-05659-5.00069-3 – ident: e_1_2_7_43_1 doi: 10.1164/rccm.200505-740OC – ident: e_1_2_7_19_1 doi: 10.1080/01902140802220625 – ident: e_1_2_7_31_1 doi: 10.1016/j.jaci.2006.07.024 – ident: e_1_2_7_25_1 doi: 10.1111/j.1398-9995.2007.01409.x – ident: e_1_2_7_27_1 doi: 10.1111/j.1365-2222.2009.03216.x – ident: e_1_2_7_17_1 doi: 10.1111/j.1398-9995.2009.02158.x – ident: e_1_2_7_22_1 doi: 10.1111/j.1365-2222.1995.tb01000.x – ident: e_1_2_7_37_1 doi: 10.1159/000070474 – ident: e_1_2_7_23_1 doi: 10.4193/Rhino50E2 – ident: e_1_2_7_20_1 doi: 10.4168/aair.2012.4.2.68 – ident: e_1_2_7_39_1 doi: 10.1034/j.1398-9995.2003.00276.x – ident: e_1_2_7_3_1 doi: 10.4168/aair.2011.3.1.3 – volume: 264 start-page: 13801 year: 1989 ident: e_1_2_7_50_1 article-title: Functional inactivation and structural disruption of human alpha 2‐macroglobulin by neutrophils and eosinophils publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)80072-2 – ident: e_1_2_7_10_1 doi: 10.1164/ajrccm.149.4.8143059 – volume: 263 start-page: 1535 year: 1988 ident: e_1_2_7_48_1 article-title: Human transforming growth factor beta–alpha 2‐macroglobulin complex is a latent form of transforming growth factor beta publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)57337-9 – ident: e_1_2_7_11_1 doi: 10.1016/S0952-3278(03)00074-7 – ident: e_1_2_7_12_1 doi: 10.1016/j.jaci.2009.12.977 – ident: e_1_2_7_7_1 doi: 10.1016/S1081-1206(10)60615-1 – ident: e_1_2_7_30_1 doi: 10.1007/s11882-006-0035-2 – ident: e_1_2_7_32_1 doi: 10.1067/mai.2003.1487 – ident: e_1_2_7_4_1 doi: 10.1111/j.1398-9995.2011.02557.x – ident: e_1_2_7_18_1 doi: 10.1378/chest.128.5.3127 – ident: e_1_2_7_51_1 doi: 10.1016/j.atherosclerosis.2005.11.035 – ident: e_1_2_7_36_1 doi: 10.1067/mai.2003.25 – ident: e_1_2_7_15_1 doi: 10.1002/jlb.55.2.183 – ident: e_1_2_7_16_1 doi: 10.1046/j.1365-2222.2002.01384.x – ident: e_1_2_7_8_1 doi: 10.1016/j.jaci.2005.08.035 – ident: e_1_2_7_26_1 doi: 10.1034/j.1398-9995.2002.t01-1-13447.x – ident: e_1_2_7_35_1 doi: 10.1016/S1081-1206(10)62815-3 – ident: e_1_2_7_45_1 doi: 10.1194/jlr.M004549 – ident: e_1_2_7_5_1 doi: 10.1016/S1081-1206(10)62084-4 – ident: e_1_2_7_28_1 doi: 10.1016/j.jaci.2008.07.034 – ident: e_1_2_7_38_1 doi: 10.1111/j.1365-2222.1996.tb00612.x – ident: e_1_2_7_34_1 doi: 10.1136/thx.2008.101196 – ident: e_1_2_7_46_1 doi: 10.1378/chest.11-0158 |
SSID | ssj0003598 |
Score | 2.242018 |
Snippet | Summary
Background
Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin‐exacerbated respiratory disease (AERD).
Objective... Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). To investigate the mechanism... Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). Objective... Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD).BACKGROUNDEosinophil... Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). To investigate the mechanism... |
SourceID | proquest pubmed crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 730 |
SubjectTerms | Adult alpha-Macroglobulins - metabolism Apolipoprotein A-I - metabolism aspirin-exacerbated respiratory disease Asthma, Aspirin-Induced - metabolism Asthma, Aspirin-Induced - pathology Biomarkers - metabolism Ceruloplasmin - metabolism CysLT Cysteine - metabolism eosinophil Eosinophil Cationic Protein - metabolism Eosinophils - metabolism Eosinophils - pathology Female Humans Inflammation - metabolism Inflammation - pathology Inflammation Mediators - metabolism Leukotrienes - metabolism Male Middle Aged Nasal Lavage Fluid Nasal Provocation Tests proteomics Proteomics - methods Respiratory Mucosa - metabolism Respiratory Mucosa - pathology |
Title | Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD |
URI | https://api.istex.fr/ark:/67375/WNG-V63DN6KD-L/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcea.12096 https://www.ncbi.nlm.nih.gov/pubmed/23786280 https://www.proquest.com/docview/1529520259 https://www.proquest.com/docview/1370636640 https://www.proquest.com/docview/1399920365 |
Volume | 43 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1365-2222 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0003598 issn: 0954-7894 databaseCode: ABDBF dateStart: 19890101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0954-7894 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1365-2222 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003598 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB1VRSBeuBQogYIMQqgvWWVjO3HE06q7pQK6DxWFIiFFtuOIVVdJtRcEPPEJfCNfwoxzgaKCEG-Rcqwk9kx87BmfAXhS8sykhraXXCRCoY0MVcmLUCupdOpUnPk6ZIfT5OBYvDiRJxvwrDsL0-hD9Btu5Bn-f00Ors3yFye3Tg_o4CfJbQ-59CHao5_SUaRM1-jsiTBVmWhVhSiLp295bi66RN366SKieZ63-oln_zq87165yTc5HaxXZmC__Kbm-J_fdAOutYSUjRoLugkbrtqCy02Jys9bcOWwDb7fgneTejmr6rMPszmj4xDNZi7TVcGq-qObM38Khar3sFnFkFgyTWH8WfX96zdc-aMNIVAv8WGLJjHXEW40ORrfhuP9yeu9g7CtzBBakUVJmNrMoONbwa1S3KgIh5XHtrA035mS_gqlTofC8kLikgwpo3VZEQnNlcJZueR3YLOqK3cXWFmWXDuZWqWdECbKTCwQWUgTO2UKHcBuN0a5bWXLqXrGPO-WL9hpue-0AB730LNGq-Mi0FM_0D1CL04puS2V-dvp8_xNwsfT5OU4fxXATmcJeevXy3xIcdEYeWIWwKP-NnokhVl05eo1YniKvC9JRPQ3DBJzigHLALYbK-tfKOYpLjMVtt71tvLnb8n3JiN_ce_foffhauwrelDG8Q5srhZr9wB51co89A70AzlXHL8 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVjwuPMorUCAghHrJKo2dxJG4rLpbFrq7h6qF9oAs23HEqquk2gcCTvwEfiO_hBknGygqCHGLlM-KY8_Yn2fGMwDPC5bpVJN5yYY84ErHgShYHigRC5VaEWWuDtlonAyO-Jvj-HgNXq7uwtT5IVqDG2mGW69Jwckg_YuWG6s6dPMzuQQb5J8jtewd_EweRbnp6kx7PEhFxpu8QhTH0zY9txtt0MB-uohqnmeubuvZuwHvV52uI05OO8uF7pgvv-Vz_N-_ugnXG07qd2shugVrttyEy3WVys-bcGXU-N9vw0m_mk_K6uzDZOrTjYjanuurMvfL6qOd-u4iChXw8Selj9zSV-TJn5Tfv37Dwz-KEQLVHD82q2NzLeG6_YPeHTja6x_uDoKmOENgeBYmQWoyjbpvODNCMC1CnFkWmdzQlqcLWhgKle5ww_IYT2XIGo3N8pArJgRuzAW7C-tlVdr74BdFwZSNUyOU5VyHmY44IvNYR1boXHmwvZokaZrM5VRAYypXJxgcNOkGzYNnLfSsTtdxEeiFm-kWoWanFN-WxvLd-JV8m7DeONnvyaEHWytRkI1qz-UOuUYjpIqZB0_b16iU5GlRpa2WiGEpUr8k4eHfMMjNyQ0ce3CvFrO2QxFL8aQpsPW2E5Y__4vc7Xfdw4N_hz6Bq4PD0VAOX4_3H8K1yBX4oADkLVhfzJb2EdKshX7stOkH9BUg2w |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB2VVlS8cCmXBgoEhFBfskpjJ3HE06q7S6HtClUUWgnJsh1HXXWVrPaCgCc-gW_kS5hxsoGighBvkXKsOPaMfcYzngF4VrBMp5qOl2zIA650HIiC5YESsVCpFVHm6pAdDpO9Y_76JD5ZgRfLuzB1foj2wI00w63XpOCTvPhFyY1VHbr4mVyBNZ6gdUWM6Ohn7ihKTVcn2uNBKjLepBWiMJ626YXNaI3G9dNlTPMicXU7z-AGfFj2uQ44Oe8s5rpjvvyWzvE_f-omXG8Yqd-tRegWrNhyA67WNSo_b8D6YeN9vw2n_Wo2KqvJ2Wjs032I-jTXV2Xul9VHO_bdNRQq3-OPSh-Zpa_Ijz8qv3_9hqY_ChEC1Qw_Nq0jcy3huv2j3h04HvTf7u4FTWmGwPAsTILUZBo133BmhGBahDivLDK5oQ1PF7QsFCrd4YblMdpkyBmNzfKQKyYEbssFuwurZVXaTfCLomDKxqkRynKuw0xHHJF5rCMrdK482F7OkTRN3nIqnzGWS_sFB026QfPgaQud1Mk6LgM9dxPdItT0nKLb0li-H76U7xLWGyb7PXngwdZSEmSj2DO5Q47RCIli5sGT9jWqJPlZVGmrBWJYisQvSXj4Nwwyc3ICxx7cq6Ws7VDEUrQzBbbedrLy53-Ru_2ue7j_79DHsP6mN5AHr4b7D-Ba5Kp7UPTxFqzOpwv7EDnWXD9yuvQDeG8fig |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Eosinophil+activation+and+novel+mediators+in+the+aspirin-induced+nasal+response+in+AERD&rft.jtitle=Clinical+and+experimental+allergy&rft.au=Choi%2C+G-S&rft.au=Kim%2C+J-H&rft.au=Shin%2C+Y-S&rft.au=Ye%2C+Y-M&rft.date=2013-07-01&rft.issn=0954-7894&rft.eissn=1365-2222&rft.volume=43&rft.issue=7&rft.spage=730&rft.epage=740&rft_id=info:doi/10.1111%2Fcea.12096&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-7894&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-7894&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-7894&client=summon |